Bridging the Gap: Multidisciplinary Collaboration in Early Breast Cancer Care
June 18th 2024The panelists share their concluding thoughts on the importance of collaboration between academic and community practices to achieve the best outcomes for their patients, which includes seeking second opinions and incorporating insights from tumor board discussions.
Navigating Therapy Approval for Early Breast Cancer: An Operational Perspective
June 18th 2024Medical experts discuss their perspectives on therapy approval and the significance of formulary inclusion, emphasizing the need to carefully consider both toxicities and benefits, which may ultimately lead to the operationalization of a drug in clinical practice.
Public Health Matters Video: Generative AI and the Future of Pharmacy
June 13th 2024Tune into this episode of “Public Health Matters” to hear Dr. Bolu Oladini’s unconventional journey within pharmacy, his passion for mental health, and how artificial intelligence is beginning to be integrated into health care and everyday life.
Understanding RSV Infection Patterns and Seasonal Outbreaks
June 11th 2024The key opinion leaders examine the current prevalence of RSV infections and its evolution over time, analyzing the seasonal patterns of RSV outbreaks in the United States and identifying the demographic groups most vulnerable to RSV infections.
Alternative Treatments for eBC and mBC
June 11th 2024Key opinion leaders (KOLs) discuss the use of CDK4/6 inhibitors in early breast cancer, specifically in patients who have undergone chemotherapy and surgery. They highlight the key factors that help determine which patients are most likely to benefit from receiving these medications.
Balancing Clinical and Economic Factors in Early Breast Cancer Treatment
June 11th 2024The panelists discuss the clinical and economic factors that influence treatment decisions for early breast cancer (eBC), as well as the differences between eBC and metastatic breast cancer (mBC) in terms of adverse event management protocols and strategies for optimizing patient adherence.
Defining the Standard of Care for Early Breast Cancer Treatment
June 4th 2024Heather Moore, BCOP, CPP, PharmD, discusses the importance of treatment for early breast cancer, highlighting the use of chemotherapy followed by endocrine therapy. She notes that CDK4/6 inhibitors are being added for higher-risk patients, and oral selective estrogen receptor degraders may also be used in advanced cases.
Academic and Community Practice Collaboration in mBC Treatment
June 4th 2024Frank Scimeca, PharmD, MBA, BCOP, discusses the crucial collaborative effort between academic and community practices in managing and monitoring patients receiving CDK4/6 inhibitors, emphasizing the importance of communication and coordination to ensure optimal patient care.
Empowering RSV Patients: Essential Vaccine Education Resources
June 4th 2024Medical professionals discuss the ongoing requirements in RSV treatment and vaccination, stressing the importance of at-risk populations maintaining hand hygiene, staying home when sick, and avoiding large crowds during peak seasons to minimize transmission, while also exploring the use of combination tests, panel testing, and rapid testing for RSV diagnosis.
Unmet Needs in Prevention and Management of RSV
June 4th 2024Rodney E. Rohde, PhD, SM, SV, MB (ASCP), FACSc, guides a conversation on patient education materials, recommending resources from the American Pharmacists Association, the Centers for Disease Control and Prevention, and the Advisory Committee on Immunization Practices, which provide tools to inform the public about vaccine-preventable diseases.
Sustained MRD-Negativity With Sc Daratumumab in Newly Diagnosed Multiple Myeloma
June 4th 2024Data from the PERSEUS trial supports use of daratumumab in combination with bortezomib, lenalidomide, and dexamethasone followed by daratumumab and lenalidomide maintenance as a new standard of care for patients with newly diagnosed multiple myeloma.
Enhanced Front Line Therapy for NDMM: Promising Results from the MajesTEC-7 Trial
June 4th 2024Results from the initial safety run-in of MajesTEC-7 indicate that the combination of teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma (NDMM) shows a manageable safety profile with early signs of efficacy.
Public Health Matters Video: Suicide Prevention and Reducing Mental Health Stigma
May 30th 2024Tune into this special episode of “Public Health Matters” to hear Emma White, the founder and president of the nonprofit organization Life Is Worth It, discuss her mental health journey and how she used it to educate adolescents, teenagers, and young adults on mental wellness.
Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting
May 29th 2024Ke Ning, MD, describes similarities and differences when implementing bispecific antibodies and CAR T-cell therapy for patients with relapsed or remitting multiple myeloma in the community oncology setting.